Birdsall TC. 5-Hydroxytryptophan: A Clinically-Effective Serotonin Precursor. Altern Med Rev 1998;3:271-80.
Michelson D, Page SW, Casey R, et al. An eosinophilia-myalgia syndrome related disorder associated with exposure to L-5-hydroxytryptophan. J Rheumatol 1994;21:2261-5.
Nakajima T, Kudo Y, Kaneko Z. Clinical evaluation of 5-hydroxy-L-tryptophan as an antidepressant drug. Folia Psychiatr Neurol Jpn 1978;32:223-30.
Sarzi Puttini P, Caruso I. Primary fibromyalgia syndrome and 5-hydroxy-L-tryptophan: a 90-day open study. J Int Med Res 1992;20:182-9.
Cangiano C, Ceci F, Cancino A, et al. Eating behavior and adherence to dietary prescriptions in obese adult subjects treated with 5-hydroxytryptophan. Am J Clin Nutr 1992;56:863-7.
Kahn RS, Westenberg HG. L-5-hydroxytryptophan in the treatment of anxiety disorders. J Affect Disord 1985;8:197-200.
Trouillas P, Brudon F, Adeleine P. Improvement of cerebellar ataxia with levorotatory form of 5-hydroxytryptophan: a double-blind study with quantified data processing. Arch Neurol 1988;45:1217-22.
Meyer JS, Welch KM, Deshmukh VD, et al. Neurotransmitter precursor amino acids in the treatment of multi-infarct dementia and Alzheimer's disease. J Amer Geriat Soc 1977;25:289-98.
U.S. Food and Drug Administration. Impurities confirmed in dietary supplement 5-hydroxy-L-tryptophan. FDA Talk Paper, August 31, 1998; T98-48.
Sternberg EM, Van Woert MH, Young SN, et al. Development of a scleroderma-like illness during therapy with L-5-hydroxytryptophan and carbidopa. N Engl J Med 1980;303:782-7.
Poldinger W, Calanchini B, Schwarz W. A functional-dimensional approach to depression: serotonin deficiency as a target syndrome in a comparison of 5-hydroxytryptophan and fluvoxamine. Psychopathology 1991;24:53-81.
Ribeiro CA. L-5-Hydroxytryptophan in the prophylaxis of chronic tension-type headache: a double-blind, randomized, placebo-controlled study. Headache 2000;40:451-6.
Nardini M, De Stefano R, Iannuccelli M, et al. Treatment of depression with L-5-hydroxytryptophan combined with chlorimipramine, a double-blind study. Int J Clin Pharmacol Res 1983;3:239-50.
U. S. Food and Drug Administration, Center for Food Safety and Applied Nutrition, Office of Nutritional Products, Labeling, and Dietary Supplements. Information Paper on L-Tryptophan and 5-hydroxy-L-tryptophan, February 2001.
Singhal AB, Caviness VS, Begleiter AF, et al. Cerebral vasoconstriction and stroke after use of serotonergic drugs. Neurology 2002;58:130-3.
Johnson KL, Klarskov K, Benson LM, et al. Presence of peak X and related compounds: the reported contaminant in case related 5-hydroxy-L-tryptophan associated with eosinophilia-myalgia syndrome. J Rheumatol 1999;26:2714-7.
Caruso I, Sarzi Puttini P, Cazzola M, Azzolini V. Double-blind study of 5-hydroxytryptophan versus placebo in the treatment of primary fibromyalgia syndrome. J Int Med Res 1990;18:201-9.
Shaw K, Turner J, Del Mar C. Tryptophan and 5-hydroxytryptophan for depression. Cochrane Database Syst Rev 2002;(1):CD003198.
Byerley WF, Judd LL, Reimherr FW, Grosser BI. 5-Hydroxytryptophan: a review of its antidepressant efficacy and adverse effects. J Clin Psychopharmacol 1987;7:127-37..
Preshaw RM, Leavitt D, Hoag G. The dietary supplement 5-hydroxytryptophan and urinary 5-hydroxyindole acetic acid. CMAJ 2008;178:993.
Takahashi S, Kondo H, Kato N. Effect of l-5-hydroxytryptophan on brain monoamine metabolism and evaluation of its clinical effect in depressed patients. J Psychiatr Res 1975;12:177-87.
Joseph, M. H. and Baker, H. F. The determination of 5-hydroxytryptophan and its metabolites in plasma following administration to man. Clin.Chim.Acta 10-1-1976;72(1):125-131.
Growdon, J. H., Young, R. R., and Shahani, B. T. L-5-hydroxytryptophan in treatment of several different syndromes in which myoclonus is prominent. Neurology 1976;26(12):1135-1140.
Anderson, L. T., Herrmann, L., and Dancis, J. The effect of L-5-hydroxytryptophan on self-mutilatin in Lesch-Nyhan disease: a negative report. Neuropadiatrie. 1976;7(4):439-442.
Ciaranello, R. D., Anders, T. F., Barchas, J. D., Berger, P. A., and Cann, H. M. The use of 5-hydroxytryptophan in a child with Lesch-Nyhan syndrome. Child Psychiatry Hum Dev 1976;7(2):127-133.
Shaw, K., Turner, J., and Del Mar, C. Tryptophan and 5-hydroxytryptophan for depression. Cochrane Database.Syst Rev 2002;(1):CD003198.
George DT, Lindquist T, Rawlings RR, et al. Pharmacologic maintenance of abstinence in patients with alcoholism: no efficacy of 5-hydroxytryptophan or levodopa. Clin Pharmacol Ther 1992;52:553-60.
Victor, S. and Ryan, S. W. Drugs for preventing migraine headaches in children. Cochrane Database.Syst.Rev 2003;(4):CD002761.
Curcio, J. J., Kim, L. S., Wollner, D., and Pockaj, B. A. The potential of 5-hydryoxytryptophan for hot flash reduction: a hypothesis. Altern Med Rev 2005;10(3):216-221.
Halladay, A. K., Wagner, G. C., Sekowski, A., Rothman, R. B., Baumann, M. H., and Fisher, H. Alterations in alcohol consumption, withdrawal seizures, and monoamine transmission in rats treated with phentermine and 5-hydroxy-L-tryptophan. Synapse 2006;59(5):277-289.
Lesch, K. P., Hoh, A., Disselkamp-Tietze, J., Wiesmann, M., Osterheider, M., and Schulte, H. M. 5-Hydroxytryptamine1A receptor responsivity in obsessive-compulsive disorder. Comparison of patients and controls. Arch Gen Psychiatry 1991;48(6):540-547.
Petre-Quadens, O. and De Lee, C. 5-Hydroxytryptophan and sleep in Down's syndrome. J Neurol Sci 1975;26(3):443-453.
Halford, J. C., Harrold, J. A., Boyland, E. J., Lawton, C. L., and Blundell, J. E. Serotonergic drugs : effects on appetite expression and use for the treatment of obesity. Drugs 2007;67(1):27-55.
Cangiano C, Ceci F, Cairella M, et al. Effects of 5-hydroxytryptophan on eating behavior and adherence to dietary prescriptions in obese adult subjects. Adv Exp Med Biol 1991;294:591-3.
Meolie, A. L., Rosen, C., Kristo, D., Kohrman, M., Gooneratne, N., Aguillard, R. N., Fayle, R., Troell, R., Townsend, D., Claman, D., Hoban, T., and Mahowald, M. Oral nonprescription treatment for insomnia: an evaluation of products with limited evidence. J Clin.Sleep Med 4-15-2005;1(2):173-187.
Morrow, J. D., Vikraman, S., Imeri, L., and Opp, M. R. Effects of serotonergic activation by 5-hydroxytryptophan on sleep and body temperature of C57BL/6J and interleukin-6-deficient mice are dose and time related. Sleep 1-1-2008;31(1):21-33.
Horvath, G. A., Stockler-Ipsiroglu, S. G., Salvarinova-Zivkovic, R., Lillquist, Y. P., Connolly, M., Hyland, K., Blau, N., Rupar, T., and Waters, P. J. Autosomal recessive GTP cyclohydrolase I deficiency without hyperphenylalaninemia: evidence of a phenotypic continuum between dominant and recessive forms. Mol.Genet.Metab 2008;94(1):127-131.
Liu, K. M., Liu, T. T., Lee, N. C., Cheng, L. Y., Hsiao, K. J., and Niu, D. M. Long-term follow-up of Taiwanese Chinese patients treated early for 6-pyruvoyl-tetrahydropterin synthase deficiency. Arch Neurol. 2008;65(3):387-392.
Jacobsen, J. P., Nielsen, E. O., Hummel, R., Redrobe, J. P., Mirza, N., and Weikop, P. Insensitivity of NMRI mice to selective serotonin reuptake inhibitors in the tail suspension test can be reversed by co-treatment with 5-hydroxytryptophan. Psychopharmacology (Berl) 2008;199(2):137-150.
Schaefer, M., Winterer, J., Sarkar, R., Uebelhack, R., Franke, L., Heinz, A., and Friebe, A. Three cases of successful tryptophan add-on or monotherapy of hepatitis C and IFNalpha-associated mood disorders. Psychosomatics 2008;49(5):442-446.
Pons, R. The phenotypic spectrum of paediatric neurotransmitter diseases and infantile parkinsonism. J Inherit.Metab Dis 2009;32(3):321-332.
Longo, N. Disorders of biopterin metabolism. J Inherit.Metab Dis 2009;32(3):333-342.
Hendricks, E. J., Rothman, R. B., and Greenway, F. L. How physician obesity specialists use drugs to treat obesity. Obesity.(Silver.Spring) 2009;17(9):1730-1735.
Chae, H. S., Kang, O. H., Choi, J. G., Oh, Y. C., Lee, Y. S., Jang, H. J., Kim, J. H., Park, H., Jung, K. Y., Sohn, D. H., and Kwon, D. Y. 5-hydroxytryptophan acts on the mitogen-activated protein kinase extracellular-signal regulated protein kinase pathway to modulate cyclooxygenase-2 and inducible nitric oxide synthase expression in RAW 264.7 cells. Biol Pharm Bull 2009;32(4):553-557.
Rothman, R. B. Treatment of obesity with "combination" pharmacotherapy. Am J Ther 2010;17(6):596-603.
Trujillo-Martin, M. M., Serrano-Aguilar, P., Monton-Alvarez, F., and Carrillo-Fumero, R. Effectiveness and safety of treatments for degenerative ataxias: a systematic review. Mov Disord. 6-15-2009;24(8):1111-1124.
Shell W, Bullias D, Charuvastra E, et al. A randomized, placebo-controlled trial of an amino acid preparation on timing and quality of sleep. Am J Ther 2010;17:133-9.
Maissen CP, Ludin HP. [Comparison of the effect of 5-hydroxytryptophan and propranolol in the interval treatment of migraine]. Schweiz Med Wochenschr 1991;121:1585-90.
Rondanelli M, Klersy C, Iadarola P, et al. Satiety and amino-acid profile in overweight women after a new treatment using a natural plant extract sublingual spray formulation. Int J Obes (Lond) 2009;33:1174-1182.
Weeks, B. S. Formulations of dietary supplements and herbal extracts for relaxation and anxiolytic action: Relarian. Med Sci Monit. 2009;15(11):RA256-RA262.
Freedman RR. Treatment of menopausal hot flashes with 5-hydroxytryptophan. Maturitas 2010;65:383-5.
Leu-Semenescu, S., Arnulf, I., Decaix, C., Moussa, F., Clot, F., Boniol, C., Touitou, Y., Levy, R., Vidailhet, M., and Roze, E. Sleep and rhythm consequences of a genetically induced loss of serotonin. Sleep 3-1-2010;33(3):307-314.
Iovieno, N., Dalton, E. D., Fava, M., and Mischoulon, D. Second-tier natural antidepressants: review and critique. J Affect.Disord. 2011;130(3):343-357.
Gendle, M. H. and Golding, A. C. Oral administration of 5-hydroxytryptophan (5-HTP) impairs decision making under ambiguity but not under risk: evidence from the Iowa Gambling Task. Hum Psychopharmacol. 2010;25(6):491-499.
Cross, D. R., Kellermann, G., McKenzie, L. B., Purvis, K. B., Hill, G. J., and Huisman, H. A randomized targeted amino acid therapy with behaviourally at-risk adopted children. Child Care Health Dev. 2011;37(5):671-678.
Adamsen, D., Meili, D., Blau, N., Thony, B., and Ramaekers, V. Autism associated with low 5-hydroxyindolacetic acid in CSF and the heterozygous SLC6A4 gene Gly56Ala plus 5-HTTLPR L/L promoter variants. Mol.Genet.Metab 2011;102(3):368-373.
den Boer JA, Westenberg HG. Behavioral, neuroendocrine, and biochemical effects of 5-hydroxytryptophan administration in panic disorder. Psychiatry Res 1990;31:267-78.
Bainbridge, M. N., Wiszniewski, W., Murdock, D. R., Friedman, J., Gonzaga-Jauregui, C., Newsham, I., Reid, J. G., Fink, J. K., Morgan, M. B., Gingras, M. C., Muzny, D. M., Hoang, L. D., Yousaf, S., Lupski, J. R., and Gibbs, R. A. Whole-genome sequencing for optimized patient management. Sci Transl.Med 6-15-2011;3(87):87re3.
Morrison, K. E. Whole-genome sequencing informs treatment: personalized medicine takes another step forward. Clin Chem 2011;57(12):1638-1640.
Horvath, G. A., Selby, K., Poskitt, K., Hyland, K., Waters, P. J., Coulter-Mackie, M., and Stockler-Ipsiroglu, S. G. Hemiplegic migraine, seizures, progressive spastic paraparesis, mood disorder, and coma in siblings with low systemic serotonin. Cephalalgia 2011;31(15):1580-1586.
Dill, P., Wagner, M., Somerville, A., Thony, B., Blau, N., and Weber, P. Child neurology: paroxysmal stiffening, upward gaze, and hypotonia: hallmarks of sepiapterin reductase deficiency. Neurology 1-31-2012;78(5):e29-e32.
Sarris, J. Clinical depression: an evidence-based integrative complementary medicine treatment model. Altern.Ther.Health Med. 2011;17(4):26-37.
Jukic T, Rojc B, Boben-Bardutzky D, Hafner M, Ihan A. The use of a food supplementation with D-phenylalanine, L-glutamine and L-5-hydroxytriptophan in the alleviation of alcohol withdrawal symptoms. Coll Antropol 2011;35:1225-30.
Friedman, J., Roze, E., Abdenur, J. E., Chang, R., Gasperini, S., Saletti, V., Wali, G. M., Eiroa, H., Neville, B., Felice, A., Parascandalo, R., Zafeiriou, D. I., Arrabal-Fernandez, L., Dill, P., Eichler, F. S., Echenne, B., Gutierrez-Solana, L. G., Hoffmann, G. F., Hyland, K., Kusmierska, K., Tijssen, M. A., Lutz, T., Mazzuca, M., Penzien, J., Poll-The BT, Sykut-Cegielska, J., Szymanska, K., Thony, B., and Blau, N. Sepiapterin reductase deficiency: a treatable mimic of cerebral palsy. Ann Neurol. 2012;71(4):520-530.
Pan, L., McKain, B. W., Madan-Khetarpal, S., Mcguire, M., Diler, R. S., Perel, J. M., Vockley, J., and Brent, D. A. GTP-cyclohydrolase deficiency responsive to sapropterin and 5-HTP supplementation: relief of treatment-refractory depression and suicidal behaviour. BMJ Case.Rep. 2011;2011
Baraldi, S., Hepgul, N., Mondelli, V., and Pariante, C. M. Symptomatic treatment of interferon-alpha-induced depression in hepatitis C: a systematic review. J Clin Psychopharmacol. 2012;32(4):531-543.
Opladen, T., Hoffmann, G. F., and Blau, N. An international survey of patients with tetrahydrobiopterin deficiencies presenting with hyperphenylalaninaemia. J Inherit.Metab Dis 2012;35(6):963-973.
Hallin, M. L., Mahmoud, K., Viswanath, A., and Gama, R. 'Sweet Dreams', 'Happy Days' and elevated 24-h urine 5-hydroxyindoleacetic acid excretion. Ann Clin Biochem. 2013;50(Pt 1):80-82.
Zarcone, V. P., Jr. and Hoddes, E. Effects of 5-hydroxytryptophan on fragmentation of REM sleep in alcoholics. Am J Psychiatry 1975;132(1):74-76.
Jangid P, Malik P, Singh P, Sharma M, Gulia AK. Comparative study of efficacy of l-5-hydroxytryptophan and fluoxetine in patients presenting with first depressive episode. Asian J Psychiatr 2013;6:29-34.
Ceci F, Cangiano C, Cairella M, et al. The effects of oral 5-hydroxytryptophan administration on feeding behavior in obese adult female subjects. J Neural Transm 1989;76:109-17.
Anders, T. F., Cann, H. M., Ciaranello, R. D., Barchas, J. D., and Berger, P. A. Further observations on the use of 5-hydroxytryptophan in a child with Lesch-Nyhan syndrome. Neuropadiatrie. 1978;9(2):157-166.
Rousseau JJ. Effects of a levo-5-hydroxytryptophan-dihydroergocristine combination on depression and neuropsychic performance: a double-blind placebo-controlled clinical trial in elderly patients. Clin Ther 1987;9:267-72.
Magnussen, I. and Nielsen-Kudsk, F. Pharmacokinetics of intravenously administered L-5-hydroxytryptophan in man. Acta Pharmacol.Toxicol.(Copenh) 1979;44(4):308-314.
Kaneko M, Kumashiro H, Takahashi Y, Hoshino Y. L-5HTP treatment and serum 5-HT level after L-5-HTP loading on depressed patients. Neuropsychobiology 1979;5:232-40.
Nolen, W. A., van de Putte, J. J., Dijken, W. A., Kamp, J. S., Blansjaar, B. A., Kramer, H. J., and Haffmans, J. Treatment strategy in depression. II. MAO inhibitors in depression resistant to cyclic antidepressants: two controlled crossover studies with tranylcypromine versus L-5-hydroxytryptophan and nomifensine. Acta Psychiatr.Scand 1988;78(6):676-683.
Zmilacher, K., Battegay, R., and Gastpar, M. L-5-hydroxytryptophan alone and in combination with a peripheral decarboxylase inhibitor in the treatment of depression. Neuropsychobiology 1988;20(1):28-35.
De Giorgis G, Miletto R, Iannuccelli M, Camuffo M, Scerni S. Headache in association with sleep disorders in children: a psychodiagnostic evaluation and controlled clinical study-L-5-HTP versus placebo. Drugs Exp Clin Res 1987;13:425-33.
Kahn RS, Westenberg HG, Verhoeven WM, et al. Effect of a serotonin precursor and uptake inhibitor in anxiety disorders; a double-blind comparison of 5-hydroxytryptophan, clomipramine and placebo. Int Clin Psychopharmacol 1987;21:33-45.
Angst J, Woggon B, Schoepf J. The treatment of depression with L-5-hydroxytryptophan versus imipramine. Results of two open and one double-blind study. Arch Psychiatr Nervenkr 1977;224:175-86.
Sueldo, C. E., Duda, M., and Kletzky, O. A. Influence of sequential doses of 5-hydroxytryptophan on prolactin release. Am J Obstet.Gynecol. 1986;154(2):424-427.
Irwin, M. R., Marder, S. R., Fuentenebro, F., and Yuwiler, A. L-5-hydroxytryptophan attenuates positive psychotic symptoms induced by D-amphetamine. Psychiatry Res. 1987;22(4):283-289.
Santucci M, Cortelli P, Rossi PG, Baruzzi A, Sacquegna T. L-5-hydroxytryptophan versus placebo in childhood migraine prophylaxis: a double-blind crossover study. Cephalalgia 1986;6:155-7.
Titus F, Dávalos A, Alom J, Codina A. 5-Hydroxytryptophan versus methysergide in the prophylaxis of migraine. Randomized clinical trial. Eur Neurol 1986;25:327-9.
De Benedittis G, Massei R. Serotonin precursors in chronic primary headache. A double-blind cross-over study with L-5-hydroxytryptophan vs. placebo. J Neurosurg Sci 1985;29:239-48.
Nolen WA, van de Putte JJ, Dijken WA, Kamp JS. L-5HTP in depression resistant to re-uptake inhibitors. An open comparative study with tranylcypromine. Br J Psychiatry 1985;147:16-22.
Van Woert, M. H., Rosenbaum, D., Howieson, J., and Bowers, M. B., Jr. Long-term therapy of myoclonus and other neurologic disorders with L-5- hydroxytryptophan and carbidopa. N Engl J Med 1-13-1977;296(2):70-75.
Chadwick, D., Hallett, M., Harris, R., Jenner, P., Reynolds, E. H., and Marsden, C. D. Clinical, biochemical, and physiological features distinguishing myoclonus responsive to 5-hydroxytryptophan, tryptophan with a monoamine oxidase inhibitor, and clonazepam. Brain 1977;100(3):455-487.
Zarcone, V., Kales, A., Scharf, M., Tan, T. L., Simmons, J. Q., and Dement, W. C. Repeated oral ingestion of 5-hydroxytryptophan. The effect on behavior and sleep processes in two schizophrenic children. Arch Gen Psychiatry 1973;28(6):843-846.
van Praag HM, Korf J, Dols LC, Schut T. A pilot study of the predictive value of the probenecid test in application of 5-hydroxytryptophan as antidepressant. Psychopharmacologia 1972;25:14-21.
Wyatt, R. J., Vaughan, T., Galanter, M., Kaplan, J., and Green, R. Behavioral changes of chronic schizophrenic patients given L-5- hydroxytryptophan. Science 9-22-1972;177(54):1124-1126.
Chase, T. N., Ng, L. K., and Watanabe, A. M. Parkinson's disease. Modification by 5-hydroxytryptophan. Neurology 1972;22(5):479-484.
Soulairac, A. [Hypnotic action of mecloqualone. Comparison with placebo effects and secobarbital]. Presse Med 4-10-1971;79(18):817-818.
van Praag, H. and de Hann, S. Depression vulnerability and 5-hydroxytryptophan prophylaxis. Psychiatry Res. 1980;3(1):75-83.
van Praag, H. M. and de Haan, S. Chemoprophylaxis of depressions. An attempt to compare lithium with 5- hydroxytryptophan. Acta Psychiatr.Scand Suppl 1981;290:191-201.
Magnussen, I., Jensen, T. S., Rand, J. H., and Van Woert, M. H. Plasma accumulation of metabolism of orally administered single dose L- 5-hydroxytryptophan in man. Acta Pharmacol.Toxicol.(Copenh) 1981;49(3):184-189.
Magnussen, I. and Van Woert, M. H. Human pharmacokinetics of long term 5-hydroxytryptophan combined with decarboxylase inhibitors. Eur.J Clin Pharmacol 1982;23(1):81-86.
Trouillas P. Regression of cerebellar syndrome with long-term administration of 5-HTP or the combination of 5-HTP-benserazide: 21 cases with quantified symptoms processed by computer. Ital J Neurol Sci 1984;5(3):253-266.
van Praag, H. M. In search of the mode of action of antidepressants: 5-HTP/tyrosine mixtures in depression. Adv Biochem Psychopharmacol. 1984;39:301-314.
Quadbeck, H., Lehmann, E., and Tegeler, J. Comparison of the antidepressant action of tryptophan, tryptophan/5- hydroxytryptophan combination and nomifensine. Neuropsychobiology 1984;11(2):111-115.
Bono, G., Micieli, G., Sances, G., Calvani, M., and Nappi, G. L-5HTP treatment in primary headaches: an attempt at clinical identification of responsive patients. Cephalalgia 1984;4(3):159-165.
Longo G, Rudoi I, Iannuccelli M, Strinati R, Panizon F. [Treatment of essential headache in developmental age with L-5-HTP (cross over double-blind study versus placebo)]. Pediatr Med Chir 1984;6:241-5.
Pueschel SM, Reed RB, Cronk CE, Goldstein BI. 5-hydroxytryptophan and pyridoxine. Their effects in young children with Down's syndrome. Am J Dis Child 1980;134:838-44.
Trouillas, P., Garde, A., Robert, J. M., and Adeleine, P. [Regression of human cerebellar ataxia under long term administration of 5-hydroxytryptophan]. C.R.Seances Acad Sci III 1-5-1981;292(1):119-122.
Magnussen, I. and Nielsen-Kudsk, F. Bioavailability and related pharmacokinetics in man of orally administered L-5-hydroxytryptophan in steady state. Acta Pharmacol Toxicol.(Copenh) 1980;46(4):257-262.
van Hiele LJ. l-5-Hydroxytryptophan in depression: the first substitution therapy in psychiatry? The treatment of 99 out-patients with 'therapy-resistant' depressions. Neuropsychobiology 1980;6:230-40.
Thal, L. J., Sharpless, N. S., Wolfson, L., and Katzman, R. Treatment of myoclonus with L-5-hydroxytryptophan and carbidopa: clinical, electrophysiological, and biochemical observations. Ann Neurol 1980;7(6):570-576.
Trouillas, P., Garde, A., Robert, J. M., Renaud, B., Adeleine, P., Bard, J., and Brudon, F. [Regression of the cerebellar syndrome under long-term administration of 5-HTP or the combination of 5-HTP and benserazide. 26 cases quantified and treated using computer methods]. Rev Neurol.(Paris) 1982;138(5):415-435.
Thomson, J., Rankin, H., Ashcroft, G. W., Yates, C. M., McQueen, J. K., and Cummings, S. W. The treatment of depression in general practice: a comparison of L- tryptophan, amitriptyline, and a combination of L-tryptophan and amitriptyline with placebo. Psychol Med 1982;12(4):741-751.
Pranzatelli, M. R., Tate, E., Huang, Y., Haas, R. H., Bodensteiner, J., Ashwal, S., and Franz, D. Neuropharmacology of progressive myoclonus epilepsy: response to 5- hydroxy-L-tryptophan. Epilepsia 1995;36(8):783-791.
Alino, J. J., Gutierrez, J. L., and Iglesias, M. L. 5-Hydroxytryptophan (5-HTP) and a MAOI (nialamide) in the treatment of depressions. A double-blind controlled study. Int Pharmacopsychiatry 1976;11(1):8-15.
Wessel K, Hermsdörfer J, Deger K, et al. Double-blind crossover study with levorotatory form of hydroxytryptophan in patients with degenerative cerebellar diseases. Arch Neurol 1995;52:451-5.
Trouillas P, Serratrice G, Laplane D, et al. Levorotatory form of 5-hydroxytryptophan in Friedreich's ataxia. Results of a double-blind drug-placebo cooperative study. Arch Neurol 1995;52:456-60.
Bastard, J., Truelle, J. L., and Emile, J. [Effectiveness of 5 hydroxy-tryptophan in Parkinson's disease]. Nouv Presse Med 9-11-1976;5(29):1836-1837.
Frith, C. D., Johnston, E. C., Joseph, M. H., Powell, R. J., and Watts, R. W. Double-blind clinical trial of 5-hydroxytryptophan in a case of Lesch- Nyhan syndrome. J Neurol Neurosurg.Psychiatry 1976;39(7):656-662.
Pranzatelli, M. R., Tate, E., Galvan, I., and Wheeler, A. A controlled trial of 5-hydroxy-L-tryptophan for ataxia in progressive myoclonus epilepsy. Clin Neurol.Neurosurg. 1996;98(2):161-164.
Ju, C. Y. and Tsai, C. T. Serotonergic mechanisms involved in the suppression of feeding by 5-HTP in rats. Chin J Physiol 1995;38(4):235-240.
Lado-Abeal, J., Rey, C., Cabezas-Agricola, J. M., Rodriguez, A., Camarero, E., and Cabezas-Cerrato, J. L-hydroxytryptophan amplifies pulsatile secretion of LH in the follicular phase of normal women. Clin Endocrinol.(Oxf) 1997;47(5):555-563.
Cangiano C, Laviano A, Del Ben M, et al. Effects of oral 5-hydroxy-tryptophan on energy intake and macronutrient selection in non-insulin dependent diabetic patients. Int J Obes Relat Metab Disord 1998;22:648-54.
Auffret, M., Comte, H., and Bene, J. Eosinophilia-myalgia syndrome induced by L-5 hydroxytryptophane: about three cases. Fund Clin Pharmacol 2013;Suppl 1(120):poster P2-204.
Brodie HKH, Sack R, and Siever L. Clinical studies of L-5-hydroxytryptophan in depression. In: Barchas J and Usdin E. Serotonin and behavior. New York: Academic Press;1973.
Wyatt, R. J., Vaughan, T., Kaplan, J., Galanter, M., and Green, R. 5-Hydroxytryptophan and chronic schizophrenia. In: Barchas J and Usdin E. Serotonin and Behavior. New York: Acedemic Press;1973.
De Benedittis G, Massei R. 5-HT precursors in migraine prophylaxis: a double-blind cross-over study with L-5-hydroxytryptophan. Clin J Pain 1986;2:123-129.
Mathew NT. 5-hydroxytryptophan in the prophylaxis of migraine: a double-blind study. Headache 1978;18:111.
Rosano Burgio, F., Borgatti, R., Scarabello, E., and Lanzi, G. Headache in children and adolescents. Proceedings of the First International Symposium on Headache in Children and Adolecents. 1989;339-47.
Sicuteri F. 5-hydroxytryptophan in the prophylaxis of migraine. Pharmacological Research Communications 1972;4:213-218.
VanPraag, H. M. and Korf, J. 5-Hydroxytryptophan as antidepressant: The predictive value of the probenecid test. Psychopharmacol.Bull. 1972;8(4):34-35.
Klein P, Lees A, and Stern G. Consequences of chronic 5-hydroxytryptophan in parkinsonian instability of gait and balance and in other neurological disorders. Adv Neurol 1986;45:603-604.
Sano I. Therapy of depression with L-5-hydroxytryptophan (L-5-HTP). Psychiatria et Neurologia Japonicas 1972;74:584.
Bazelon M, Paine RS, Cowie VA, et al. Reversal of hypotonia in infants with Down's syndrome by administration of 5-hydroxytryptophan. Lancet 1967;1:1130-3.
Weise P, Koch R, Shaw KN, Rosenfeld MJ. The use of 5-HTP in the treatment of Down's syndrome. Pediatrics 1974;54(2)165-8.
Das YT, Bagchi M, Bagchi D, Preuss HG. Safety of 5-hydroxy-L-tryptophan. Toxicol Lett 2004;150:111-22.
U.S. Food and Drug Administration. Orphan drug designations and approvals. Available at: www.accessdata.fda.gov/scripts/opdlisting/oopd/index.cfm (accessed 8/20/2015).
U.S. Food and Drug Administration Pharmacy Compounding Advisory Committee meeting June 17-18, 2015. Available at: www.fda.gov/downloads/advisorycommittees/committeesmeetingmaterials/drugs/pharmacycompoundingadvisorycommittee/ucm455276.pdf (accessed 8/21/15).
Gendle MH, Young EL, Romano AC. Effects of oral 5-hydroxytryptophan on a standardized planning task: insight into possible dopamine/serotonin interactions in the forebrain. Hum Psychopharmacol 2013;28(3):270-3.
Chen D, Liu Y, He W, Wang H, Wang Z. Neurotransmitter-precursor-supplement intervention for detoxified heroin addicts. J Huazhong Univ Sci Technolog Med Sci 2012;32(3):422-7.
Pardo JV. Mania following addition of hydroxytryptophan to monoamine oxidase inhibitor. Gen Hosp Psychiatry 2012;34(1):102.e13-4.
Lemaire PA, Adosraku RK. An HPLC method for the direct assay of the serotonin precursor, 5-hydroxytrophan, in seeds of Griffonia simplicifolia. Phytochem Anal 2002;13(6):333-7.
Michelson D, Page SW, Casey R, et al. An eosinophilia-myaligia syndrome related disorder associated with exposure to l-5-hydroxytryptophan. J Rheumatol 1994;21(12):2261-5.
Israelyan N, Del Colle A, Li Z, et al. Effects of Serotonin and Slow-Release 5-Hydroxytryptophan on Gastrointestinal Motility in a Mouse Model of Depression. Gastroenterology. 2019;157(2):507-521.e4.
Meloni M, Puligheddu M, Carta M, Cannas A, Figorilli M, Defazio G. Efficacy and safety of 5-hydroxytryptophan on depression and apathy in Parkinson's disease: a preliminary finding. Eur J Neurol 2020;27(5):779-786.
Javelle F, Lampit A, Bloch W, Häussermann P, Johnson SL, Zimmer P. Effects of 5-hydroxytryptophan on distinct types of depression: a systematic review and meta-analysis. Nutr Rev 2020;78(1):77-88.
Yousefzadeh F, Sahebolzamani E, Sadri A, et al. 5-Hydroxytryptophan as adjuvant therapy in treatment of moderate to severe obsessive-compulsive disorder: a double-blind randomized trial with placebo control. Int Clin Psychopharmacol. 2020;35(5):254-262.
Meloni M, Puligheddu M, Sanna F, et al. Efficacy and safety of 5-Hydroxytryptophan on levodopa-induced motor complications in Parkinson's disease: A preliminary finding. J Neurol Sci. 2020;415:116869.
Maffei ME. 5-Hydroxytryptophan (5-HTP): Natural Occurrence, Analysis, Biosynthesis, Biotechnology, Physiology and Toxicology. Int J Mol Sci. 2020;22(1):181.
Zamoscik V, Schmidt SNL, Bravo R, et al. Tryptophan-enriched diet or 5-hydroxytryptophan supplementation given in a randomized controlled trial impacts social cognition on a neural and behavioral level. Sci Rep 2021;11(1):21637.
Knäpper J, Girauta MV, Coromina J. Effectiveness of Tinnitan Duo® in Subjective Tinnitus with Emotional Affectation: A Prospective, Interventional Study. J Diet Suppl 2021;1-14.
Meloni M, Figorilli M, Carta M, et al. Preliminary finding of a randomized, double-blind, placebo-controlled, crossover study to evaluate the safety and efficacy of 5-hydroxytryptophan on REM sleep behavior disorder in Parkinson's disease. Sleep Breath 2021.
Truyens M, Lobatón T, Ferrante M, et al. Effect of 5-Hydroxytryptophan on Fatigue in Quiescent Inflammatory Bowel Disease: A Randomized Controlled Trial. Gastroenterology 2022;163(5):1294-1305.
Nash E, Jamshidi N. Hippocampal ischaemia from accidental 5-Hydroxytryptophan (5-HTP) overdose case report. Clin Neurol Neurosurg 2022;220:107384.
Evans C, Mekhail V, Curtis J, et al. The Effects of 5-HTP on Body Composition: An 8-Week Preliminary RCT. J Diet Suppl 2022.
Wu L, Ran L, Wu Y, et al. Oral Administration of 5-Hydroxytryptophan Restores Gut Microbiota Dysbiosis in a Mouse Model of Depression. Front Microbiol 2022;13:864571.
Russo AM, Payet JM, Kent S, Lesku JA, Lowry CA, Hale MW. Acute treatment with 5-hydroxytryptophan increases social approach behaviour but does not activate serotonergic neurons in the dorsal raphe nucleus in juvenile male BALB/c mice: A model of human disorders with deficits of sociability. J Psychopharmacol 2022;36(7):806-818.
Sutanto CN, Xia X, Heng CW, et al. The impact of 5-hydroxytryptophan supplementation on sleep quality and gut microbiota composition in older adults: A randomized controlled trial. Clin Nutr 2024;43(3):593-602.
You Might Also Like
Select a condition to view a list of vitamins
CONDITIONS OF USE AND IMPORTANT INFORMATION: This information is meant to supplement, not replace advice from your doctor or healthcare provider and is not meant to cover all possible uses, precautions, interactions or adverse effects. This information may not fit your specific health circumstances. Never delay or disregard seeking professional medical advice from your doctor or other qualified health care provider because of something you have read on WebMD. You should always speak with your doctor or health care professional before you start, stop, or change any prescribed part of your health care plan or treatment and to determine what course of therapy is right for you.
This copyrighted material is licensed from Therapeutic Research Center, LLC. Information from this source is evidence-based and objective, and without commercial influence. For professional medical information on natural medicines, see Natural Medicines Comprehensive Database Professional Version.
Licensed from Therapeutic Research Center, LLC
Copyright © 1995-2025 by Therapeutic Research Center, LLC. All Rights Reserved.